Table 1
From the following article
Hepatitis C: staying the course
Ken Garber
Nature Biotechnology 25, 1379 - 1381 (2007)
doi:10.1038/nbt1207-1379
Table 1. Selected hepatitis C drugs in the clinic
| Molecule | Company | Target/mechanism | Clinical stage |
|---|---|---|---|
| Albuferon | Human Genome Sciences (Rockville, Maryland) | Interferon-albumin fusion protein | Phase 3 |
| Telaprevir | Vertex Pharmaceuticals (Cambridge, Massachusetts) | NS3 protease inhibitor | Phase 2 |
| Boceprevir | Schering-Plough (Kenilworth, New Jersey) | NS3 protease inhibitor | Phase 2 |
| R1626 | Roche (Basel, Switzerland) | NS5B polymerase inhibitor | Phase 2 |
| IC41 | Intercell (Vienna, Austria) | Therapeutic vaccine | Phase 2 |
| VGX-410C | VGX Pharmaceuticals (Blue Bell, Pennsylvania) | Oral IRES inhibitor | Phase 2 |
| Debio-025 | Debiopharm, S.A. (Lausanne, Switzerland) | Cyclophilin inhibitor | Phase 2 |
| Celgosivir | Migenix (Vancouver, Canada) |  -glucosidase 1 inhibitor | Phase 2 |
| SCV-07 | SciClone Pharmaceuticals (San Mateo, California) | Immune stimulant peptide | Phase 2 |
| Nitazoxanide | Romark Laboratories (Tampa, FL) | Undisclosed | Phase 2 |
| R7128 | Pharmasset (Princeton, New Jersey), Roche | NS5B polymerase inhibitor | Phase 1/2 |
| ITMN-191 | InterMune (Brisbane, California) | NS3 protease inhibitor | Phase 1b |
| GI-5005 | Globeimmune (Louisville, Kentucky) | Targeted molecular immunogen | Phase 1 |
| GS-9190 | Gilead Sciences (Foster City, California) | NS5B polymerase inhibitor | Phase 1 |
| AZD-2836 | Astra-Zeneca (London) | NS5A protein inhibitor | Phase 1 |
| IMO-2125 | Idera Pharmaceuticals (Cambridge, Massachusetts) | Toll-like receptor 9 agonist | Phase 1 |